Probes for radiotheranostics could
be produced by introducing radionuclides
with similar chemical characteristics into the same precursors. We
recently developed an 211At-labeled RGD peptide and a corresponding
radioiodine-labeled RGD peptide. Both labeled peptides accumulated
in large quantities in the tumor with similar biodistribution, demonstrating
their usefulness for radiotheranostics. In this study, we hypothesized
that probes for radiotheranostics combined with multiradionuclides,
such as 68Ga and 211At, have useful clinical
applications. New radiolabeled RGD peptide probes were synthesized
via a molecular design approach, with two labeling sites for metal
and halogen. These probes were evaluated in biodistribution experiments
using tumor-bearing mice. [67Ga]Ga-DOTA-c[RGDf(4-I)K] ([67Ga]4), Ga-DOTA-[125I]c[RGDf(4-I)K]
([125I]4), and Ga-DOTA-[211At]c[RGDf(4-At)K]
([211At]7) showed similar biodistribution,
with high and equivalent accumulation in tumors. These results indicate
the usefulness of these probes in radiotheranostics with multiradionuclides,
such as a radiometal and a radiohalogen, and they could contribute
to a personalized medicine regimen.
As sigma receptors are highly expressed on various cancer cells, radiolabeled sigma receptor ligands have been developed as imaging and therapeutic probes for cancer. Previously, we synthesized and evaluated a...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.